Shi Huang, 67San Bruno, CA

6660525, Dec 9, 2003

Feb 10, 2000

09/501857

Francis J. Martin - San Francisco CA
Samuel Zalipsky - Redwood City CA
Shi Kun Huang - Castro Valley CA

Alza Corporation - Mountain View CA

C12N 1586

435458, 435375, 424450, 530402, 530403

A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.

6958241, Oct 25, 2005

Jul 8, 2003

10/616094

Francis J. Martin - San Francisco CA, US
Samuel Zalipsky - Redwood City CA, US
Shi Kun Huang - Castro Valley CA, US

C12N015/88
C12N005/06
C12N005/12
A61K009/127

435458, 435375, 424450

A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.

6974589, Dec 13, 2005

Oct 10, 2000

09/685940

Shi Kun Huang - Castro Valley CA, US
Samuel Zalipsky - Redwood City CA, US
Wei-Ming Zhang - San Francisco CA, US
Bei Jin - Union City CA, US
Yolanda P. Quinn - Daly City CA, US

Miza Corporation - Mountain View CA

A61K009/127

424450, 424 121, 424 9321, 424 951, 424417, 4284022

A lipid represented by the formula: wherein each of Rand Ris an alkyl or alkenyl chain having between about 8 to about 24 carbon atoms; n=0–20; L is selected from the group consisting of (i) —X—(C═O)—Y—, (ii) —X—(C═O)—, and (iii) —X—CH—, wherein X and Y are independently selected from oxygen, NH, and a direct bond; and Z is a weakly basic moiety that has a pK of less than about 7. 4 and greater than about 4. 0 is described.

7108863, Sep 19, 2006

Mar 26, 2002

10/108154

Samuel Zalipsky - Redwood City CA, US
Theresa M. Allen - Edmonton, CA
Shi Kun Huang - Castro Valley CA, US

Alza Corporation - Mountain View CA

A61B 5/055
A61B 8/00
A61K 9/127

424450, 424 9321, 424 951

A liposomal composition and a method of using the same for achieving intracellular delivery of a liposome-entrapped agent is described. The liposomes are composed of a pH sensitive lipid and include a targeting ligand to direct the liposomes to a target cell. The liposomes also include a stabilizing component, such a polymer-derivatized lipid, where the polymer is attached to the lipid by a releasable linkage. Administration of the liposomes results in cellular internalization and destabilization of the liposome for intracellular delivery of the entrapped agent.

2005026, Nov 24, 2005

May 19, 2005

11/133879

Shi Huang - Castro Valley CA, US
Samuel Zalipsky - Redwood City CA, US
Wei-Ming Zhang - San Francisco CA, US
Bei Jin - Union City CA, US
Yolanda Quinn - Daly City CA, US

C07D233/54
A61K009/127

424450000, 548338100

A lipid represented by the formula: wherein each of Rand Ris an alkyl or alkenyl chain having between about 8 to about 24 carbon atoms; n=0-20; L is selected from the group consisting of (i) —X—(C═O)—Y—, (ii) —X—(C═O)—, and (iii) —X—CH—, wherein X and Y are independently selected from oxygen, NH and a direct bond; and Z is a weakly basic moiety that has a pK of less than about 7.4 and greater than about 4.0 is described.

2006024, Oct 26, 2006

Jun 20, 2006

11/472140

Samuel Zalipsky - Redwood City CA, US
Theresa Allen - Edmonton, CA
Shi Huang - Castro Valley CA, US

A61K 39/395
A61K 9/127

424144100, 424450000

A liposomal composition and a method of using the same for achieving intracellular delivery of a liposome-entrapped agent is described. The liposomes are composed of a pH sensitive lipid and include a targeting ligand to direct the liposomes to a target cell. The liposomes also include a stabilizing component, such a polymer-derivatized lipid, where the polymer is attached to the lipid by a releasable linkage. Administration of the liposomes results in cellular internalization and destabilization of the liposome for intracellular delivery of the entrapped agent.

5851818, Dec 22, 1998

Mar 28, 1997

8/827236

Shi Kun Huang - Castro Valley CA
Edwin Kiyoshi Oto - Redwood City CA
Mohammad Hassanipour - Vallejo CA
Bei Jin - Union City CA

Sequus Pharmaceuticals, Inc. - Menlo Park CA

C12N 1564
A01N 2526
B01J 1302
C12P 2102

4353201

An improvement in a method of preparing plasmid-liposome complexes for in vivo transfection is described. The improvement includes selecting a condensing agent to condense the plasmid prior to contact with the liposomes, selecting a working medium and selecting a ratio of liposome lipid to plasmid. Also disclosed are DNA plasmid-liposome complexes formed by the method.

5356633, Oct 18, 1994

Oct 7, 1992

7/958100

Martin C. Woodle - Menlo Park CA
Francis J. Martin - San Francisco CA
Shi K. Huang - Castro Valley CA

Liposome Technology, Inc. - Menlo Park CA

A61K 9127
A61K 3722

424450

A method of and composition for concentrating a therapeutic agent in an inflamed dermal region are disclosed. The composition, which is also used in the method, is a liposomal composition. The liposomes contain the therapeutic agent in entrapped form and are composed of vesicle-forming lipids including a vesicle-forming lipid derivatized with hydrophilic biocompatible polymer. After intravenous administration, the liposomes are taken up by the inflamed region within 24-48 hours, for site-specific release of entrapped compound into the inflamed region.